<?xml version="1.0" encoding="UTF-8"?><bill xmlns="http://schemas.gpo.gov/xml/uslm" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://schemas.gpo.gov/xml/uslm uslm-2.0.10.xsd" xml:lang="en"><meta><dc:title>117 S. 164 ENR: To educate health care providers and the public on biosimilar biological products, and for other purposes.</dc:title><dc:type>Senate Bill</dc:type><dc:creator>U.S. Senate</dc:creator><congress>117</congress><session>1</session><docNumber>164</docNumber><docStage>ENR</docStage><citableAs>117s164enr</citableAs><citableAs>117 S. 164 ENR</citableAs><dc:format>text/xml</dc:format><dc:language>EN</dc:language><dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights><processedBy>Xcential BillDTD to USLM Converter v20210601</processedBy><processedDate>2021-11-20</processedDate><publicPrivate>public</publicPrivate></meta><preface><dc:type>S. </dc:type><docNumber>164</docNumber><congress value="117">One Hundred Seventeenth Congress of the United States of America</congress><session value="1">AT THE FIRST SESSION</session><enrolledDateline>Begun and held at the City of Washington on Sunday, the third day of January, two thousand and twenty one</enrolledDateline></preface><main id="H64A4E8894A0511EC192009173F13E4C5"><longTitle><docTitle>AN ACT</docTitle><officialTitle>To educate health care providers and the public on biosimilar biological products, and for other purposes.</officialTitle></longTitle><enactingFormula>Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,</enactingFormula><section identifier="/s1" id="id00D8C00ACC224A3F9A5C6C7CA80DCAF1" class="bill-dtd-OLC"><num value="1">SECTION 1.</num><heading> SHORT TITLE.</heading><content class="indent0">This Act may be cited as the “<shortTitle>Advancing Education on Biosimilars Act of 2021</shortTitle>”.</content></section><section identifier="/s2" id="idB91E21E39B0640589EDCEDC1B897872A" class="bill-dtd-OLC"><num value="2">SEC. 2.</num><heading> EDUCATION ON BIOLOGICAL PRODUCTS.</heading><content><p class="indent0">Subpart 1 of part F of title III of the Public Health Service Act (<ref href="/us/usc/42/262">42 U.S.C. 262</ref> et seq.) is amended by adding at the end the following:</p><quotedContent id="idA8ED40B614CA4FD38F4A689BCA9099CE"><section identifier="/s2/qB/s352A" id="id9660188FE30E44F9B968F237FA8D8A61" class="bill-dtd-OLC"><num value="352A">“SEC. 352A.</num><heading> EDUCATION ON BIOLOGICAL PRODUCTS.</heading><subsection identifier="/s2/qB/s352A/a" id="idD56F9D725BFB4208A7B57D2FB3573F9B" class="bill-dtd-OLC"><num value="a">“(a)</num><heading> Internet Website.—</heading><paragraph identifier="/s2/qB/s352A/a/1" id="id4DC370626BFE4828A6AF4297CA7944FF" class="bill-dtd-OLC"><num value="1">“(1)</num><heading> In general.—</heading><content>The Secretary may maintain and operate an internet website to provide educational materials for health care providers, patients, and caregivers, regarding the meaning of the terms, and the standards for review and licensing of, biological products, including biosimilar biological products and interchangeable biosimilar biological products.</content></paragraph><paragraph identifier="/s2/qB/s352A/a/2" id="id3DFF3BD9F8434C2EA8DBE42ACD7F687A" class="bill-dtd-OLC"><num value="2">“(2)</num><heading> Content.—</heading><chapeau>Educational materials provided under paragraph (1) may include—</chapeau><subparagraph identifier="/s2/qB/s352A/a/2/A" id="id5A2AF9E731FD412ABC9577E019BFDBF0" class="bill-dtd-OLC" role="definitions"><num value="A">“(A)</num><content> explanations of key statutory and regulatory terms, including ‘<term>biosimilar</term>’ and ‘<term>interchangeable</term>’, and clarification regarding the use of interchangeable biosimilar biological products;</content></subparagraph><subparagraph identifier="/s2/qB/s352A/a/2/B" id="id0F7C454773A047CEA66DE6C4DFD1EDF2" class="bill-dtd-OLC"><num value="B">“(B)</num><content> information related to development programs for biological products, including biosimilar biological products and interchangeable biosimilar biological products and relevant clinical considerations for prescribers, which may include, as appropriate and applicable, information related to the comparability of such biological products;</content></subparagraph><subparagraph identifier="/s2/qB/s352A/a/2/C" id="id2EA125266B124E71BEB7452B4267861C" class="bill-dtd-OLC"><num value="C">“(C)</num><content> an explanation of the process for reporting adverse events for biological products, including biosimilar biological products and interchangeable biosimilar biological products; and</content></subparagraph><subparagraph identifier="/s2/qB/s352A/a/2/D" id="id01605666F7AF4DC1A33F5DFA7448794D" class="bill-dtd-OLC"><num value="D">“(D)</num><content> an explanation of the relationship between biosimilar biological products and interchangeable biosimilar biological products licensed under section 351(k) and reference products (as defined in section 351(i)), including the standards for review and licensing of each such type of biological product.</content></subparagraph></paragraph><paragraph identifier="/s2/qB/s352A/a/3" id="idB89139BFC88E49BDB14FEB072AC4F232" class="bill-dtd-OLC"><num value="3">“(3)</num><heading> Format.—</heading><chapeau>The educational materials provided under paragraph (1) may be—</chapeau><subparagraph identifier="/s2/qB/s352A/a/3/A" id="id67253B42C91347048B49CB5FBDA0440E" class="bill-dtd-OLC"><num value="A">“(A)</num><content> in formats such as webinars, continuing education modules, videos, fact sheets, infographics, stakeholder toolkits, or other formats as appropriate and applicable; and</content></subparagraph><subparagraph identifier="/s2/qB/s352A/a/3/B" id="idF37052146CB24739B067409631F92B8D" class="bill-dtd-OLC"><num value="B">“(B)</num><content> tailored for the unique needs of health care providers, patients, caregivers, and other audiences, as the Secretary determines appropriate.</content></subparagraph></paragraph><paragraph identifier="/s2/qB/s352A/a/4" id="id5E0EB08DABE649799CEB53567EA5D813" class="bill-dtd-OLC"><num value="4">“(4)</num><heading> Other information.—</heading><chapeau>In addition to the information described in paragraph (2), the Secretary shall continue to publish—</chapeau><subparagraph identifier="/s2/qB/s352A/a/4/A" id="id41D68429460249F28BF8DE6346CE1543" class="bill-dtd-OLC"><num value="A">“(A)</num><content> the action package of each biological product licensed under subsection (a) or (k) of section 351; or</content></subparagraph><subparagraph identifier="/s2/qB/s352A/a/4/B" id="id368ABD1F26084312A5765A01D189C329" class="bill-dtd-OLC"><num value="B">“(B)</num><content> the summary review of each biological product licensed under subsection (a) or (k) of section 351.</content></subparagraph></paragraph><paragraph identifier="/s2/qB/s352A/a/5" id="id8DA9FC177FD144D39CD7C34EE0B284EE" class="bill-dtd-OLC"><num value="5">“(5)</num><heading> Confidential and trade secret information.—</heading><content>This subsection does not authorize the disclosure of any trade secret, confidential commercial or financial information, or other matter described in section 552(b) of title 5.</content></paragraph></subsection><subsection identifier="/s2/qB/s352A/b" id="idB106A8F8F3BC456995B3C92D44962F5F" class="bill-dtd-OLC"><num value="b">“(b)</num><heading> Continuing Education.—</heading><content>The Secretary shall advance education and awareness among health care providers regarding biological products, including biosimilar biological products and interchangeable biosimilar biological products, as appropriate, including by developing or improving continuing education programs that advance the education of such providers on the prescribing of, and relevant clinical considerations with respect to, biological products, including biosimilar biological products and interchangeable biosimilar biological products.”</content></subsection></section></quotedContent>. </content></section></main><signatures><signature><name/><role>Speaker of the House of Representatives</role></signature><signature><name/><role>Vice President of the United States and President of the Senate</role></signature></signatures></bill>